A new male birth control method may be on the horizon, as the initial results of a clinical trial have shown that injecting a degradable hydrogel into the vas deferens is a possible solution. Developed under the name ADAM system, this biocompatible hydrogel is designed to prevent sperm from traveling through the vas deferens without affecting sensation or ejaculation. The hydrogel is injected and thickens inside the body, leading to sperm-free semen within only 30 days of implantation. This form of male contraception is reversible, making it an attractive option for those who no longer desire biological children. These initial results were obtained through a first-in-human clinical trial that included four men. The trial led by the principal investigator, Dr. Paul Anderson, has shown a low potential for harm and a favorable safety profile for the ADAM system, suggesting primary endpoints will be met. Researchers are looking to eventually conduct implantations in 25 healthy and fertile men who are suitable for a vasectomy.
